Slide 1: Life Sciences Forum June 24, 2026
| 1 1 NASDAQ: CTSO Life Sciences Forum June 24, 2026
Slide 2: Safe Harbor Statement
| 2 2 Safe Harbor Statement Statements in this presentation include forward - looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward - looking statements include, but are not limited to, statements
Slide 3: Regulatory Disclaimer
| 3 3 Regulatory Disclaimer Cyto Sorb • CE Marked in Europe for the following APPROVED Indications for Use: • Cytokine Removal • Bilirubin and Myoglobin Removal • Ticagrelor and Rivaroxaban removal during cardiothoracic surgery • CytoSorb is NOT yet cleared/approved by the FDA or Health Canada DrugS
Slide 4: CytoSorbents Overview
| 4 | 4 Cyto Sorbents Overview • U.S. - based medical device company (Nasdaq: CTSO) specializing in blood purification to treat life - threatening conditions in the intensive care unit and cardiac surgery with its proprietary, biocompatible, porous polymer bead technology • CytoSorb , the first and
Slide 5: The Power of the Bead
5 The Power of the Bead • Excellent removal of a broad range of substances from whole blood and plasma • Solid state porous polymer chemistry that does not use ligands, antibodies, cells, or biologics • 20 issued U.S. patents and multiple patents issued and pending worldwide Hemocompatible , highly
Slide 6: We are an Innovation Leader in Acute Care Blood Purification
6 Status Pivotal Pilot Pre - Clinical Application Pipeline Product US De Novo Submission – Late 2026/Early 2027 Removal of antithrombotic drugs FDA Pre - IDE feedback scheduled in July. Clinical trials expected 2027 Universal Blood Products Pipeline Successor to CytoSorb Pipeline CT Imaging and inte
Slide 7: Products are Plug and Play Compatible
| 7 Products are “Plug and Play” Compatible Compatible with Existing Blood Pump Infrastructure In Hospitals Today ECMO (Extracorporeal Membrane Oxygenation) CPB (Cardiopulmonary Bypass) Dialysis or CRRT (Continuous Renal Replacement Therapy) CytoSorbents Confidential Hemoperfusion (Standalone Treatm
Slide 8: CytoSorb Our Core Business
| 8 Cyto Sorb Our Core Business C ytoSorb is E.U. CE Mark approved but not yet cleared or approved in the U.S./Canada
Slide 9: CytoSorb is a powerful blood purification technology
| 9 CytoSorb is a powerful blood purification technology CE - mark approved in the E.U. to reduce cytokines, bilirubin, myoglobin, and blood thinners like ticagrelor & rivaroxaban. It removes many substances that dialysis cannot. Dialysis is designed to work like the kidney Small Molecules and Water
Slide 10: Uncontrolled Massive Inflammation - the Heart of Critical Illness
| 10 10 Uncontrolled Massive Inflammation - the Heart of Critical Illness • Acute inflammation is the body’s mechanism to fight injury and infection • However, severe inflammation, driven by cytokine storm, can cause a chain reaction of problems that can end in organ failure and death • Severe infla
Slide 11: Targets Deadly Conditions That Afflict Millions of People
| 11 11 Targets Deadly Conditions That Afflict Millions of People Lung Injury Burn Injury S e psis COVID - 19 Influenza Cytokine Release Syndrome Surgical Complications Liver Failure T rauma Critical Care Cardiothoracic Surgery Removes the “fuel to the fire” of massive uncontrolled inflammation that
Slide 12: CytoSorb Has Much Larger ICU Opportunity than Dialysis
| 12 100% CytoSorb Has Much Larger ICU Opportunity than Dialysis 80% 60% 40% 20% Dialysis/CRRT for Kidney Failure CytoSorbents Sepsis, Septic Shock, Other Shock Infectious diseases (flu, COVID - 19, other) Burn injury Drug overdose Blood thinner toxicity Trauma, Rhabdomyolysis Cytokine storm/ Cytoki
Slide 13: CytoSorb Supported by a Wealth of Clinical Data
| 13 CytoSorb Supported by a Wealth of Clinical Data
Slide 14: Right Patient, Right Timing, Right Dosing
| 14 Highest Chance for Good Cinical Outcome Right Patient Right Dose Right Timing The Key to Success: Right Patient, Right Timing, Right Dosing Just like antibiotics, CytoSorb works most effectively when: • Treat Early • Treat Intensively • Compete the Full Course of Treatment Before After
Slide 15: CytoSorbents is Leading a New Era in Sepsis Treatment
| 15 CytoSorbents is Leading a New Era in Sepsis Treatment One in 5 deaths is related to sepsis. For more than a decade, CytoSorbents has collaborated with clinicians and scientists around the world to advance the treatment of sepsis and septic shock by complementing traditional antibiotics with the
Slide 16: Turning the Tide of Sepsis and Septic Shock: Real World Insights with CytoSorb
| 16 Turning the Tide of Sepsis and Septic Shock: Real World Insights with CytoSorb September 10, 2025 Link to webinar replay: https://cyto.news/webinar - sepsis/sep10
Slide 17: The Opportunity of DrugSorb-ATR
| 17 The Opportunity of DrugSorb - ATR is an investigational device that is not yet cleared/approved by FDA, Health Canada, or by any other Global Regulatory Agency and is not commercially available for sale
Slide 18: Blood Thinners and Cardiac Surgery
| 18 Blood Thinners and Cardiac Surgery • Tens of millions of patients globally take Direct Oral Anticoagulants ( e.g , DOACs like Eliquis ® and Xarelto ® ) and antiplatelet agents ( e.g , Brilinta ® ) either chronically or acutely to reduce risk of heart attack, stroke, and other serious thrombotic
Slide 19: Brilinta and the Use Case for DrugSorb-ATR
| 19 Brilinta ® and the Use Case for 5 - 10% will need open heart surgery X X X X X The ultimate goal of DrugSorb - ATR is to allow patients to get the critical surgery they need without delay while reducing or preventing bleeding complications DrugSorb - ATR is an investigational device in th e U.S
Slide 20: The Pivotal STAR-T RCT Paper Is Now Published
| 20 The Pivotal STAR - T RCT Paper Is Now Published DrugSorb - ATR is an investigational device in th e U.S. and Canada and not yet cleared/approved Mack, M, et al. J Thorac Cardiovasc Surg. 2026. Online ahead of print
Slide 21: FDA Regulatory Update for DrugSorb-ATR and Brilinta
| 21 FDA Regulatory Update for DrugSorb - ATR and Brilinta ® • FDA Appeal Decision of the original De Novo submission (August 20, 2025) • Upheld the prior denial decision based on missing primary endpoint of STAR - T pivotal trial, and required additional information primarily based on real - world
Slide 22: Potential Second Shot on Goal: DOAC Removal
| 22 Potential Second Shot on Goal: DOAC Removal • We have previously discussed our intention to pursue an expanded label for DrugSorb - ATR to include removal of DOACs following an initial marketing approval. Meanwhile, real - world evidence and publications continue to grow for this indication • W
Slide 23: Large Total Addressable Market
| 23 >$300M Initial Opportunity • U.S. & CAN Ticagrelor Removal in CABG >$200M >$450M Future Opportunity $1 - 2 Billion • U.S. & CAN Ticagrelor Removal in CABG • DOAC Removal in CABG • DOAC Removal in Hospital - Wide Applications >$150M >$450M Near - Term Opportunity >$600M • Expansion of U.S. & CAN
Slide 24: Financial Performance
| 24 | 24 Financial Performance
Slide 25: CytoSorb Commercialization Focus
| 25 25 Cyto Sorb Commercialization Focus Estimated Revenue By Market Revenue By Geography 17% 33% 50% Other Critical Care 17% Sepsis and Septic Shock Other Critical Care: 17% Cardiac Surgery • ARDS • Reversal of Shock • Trauma • Acute Liver / Pancreatic • Many Others 44% 24% 32% Critical Care Overa
Slide 26: A History of Strong Annual Sales Growth
| 26 A History of Strong Annual Sales Growth Q1 2026 Performance • Q1 2026 Sales were $8.9M, +2% vs $8.7M a year ago. Trailing 12 - month sales were $37.3M • 13% growth in Direct Sales outside Germany • Germany did well in midst of restructuring, achieving sales just slightly below last year with fe
Slide 27: Driving to Cash Flow Breakeven in 2H 2026
| 27 • Making good progress in driving improved negative free cash flow through efficiency development, cash management, and cost reductions • We now expect to be operating cash flow break even in the second half of 2026 • Ended Q1 2026 with $6.4 million in cash, cash equivalents and restricted cash
Slide 28: A Clear and Compelling Value Proposition
| 28 28 A Clear and Compelling Value Proposition We believe CytoSorbents is significantly undervalued and have a sound plan to build and maximize shareholder value CytoSorb is an established, international core business in critical care and cardiac surgery with $37.3M in high margin product sales (
Slide 29: Company Contact
Company Contact: Dr. Phillip Chan pchan@cytosorbents.com www.cytosorbents.com NASDAQ: CTSO 29 CytoSorbents Corporation